FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034932355> ?p ?o ?g. }

• W2034932355 endingPage "846" @default.
• W2034932355 startingPage "843" @default.
• W2034932355 abstract "We conducted a prospectively randomised clinical trial to investigate the role of adjuvant outpatient immunochemotherapy administered postoperatively in high-risk patients with renal cell carcinoma. In total, 203 renal carcinoma patients' status post radical tumour nephrectomy were stratified into three risk groups: patients with tumour extending into renal vein/vena cava or invading beyond Gerota's fascia (pT3b/c pN0 or pT4pN0), patients with locoregional lymph node infiltration (pN+), and patients after complete resection of tumour relapse or solitary metastasis (R0). Patients were randomised to undergo either (A) 8 weeks of outpatient subcutaneous interleukin-2 (sc-rIL-2), subcutaneous interferon-alpha2a (sc-rIFN-alpha2a), and intravenous 5-fluorouracil (iv-5-FU) according to the standard Atzpodien regimen (Atzpodien et al, 2004) or (B) observation. Two-, 5-, and 8-year survival rates were 81, 58, and 58% in the treatment arm, and 91, 76, and 66% in the observation arm (log rank P=0.0278), with a median follow-up of 4.3 years. Two, 5-, and 8-year relapse-free survival rates were calculated at 54, 42, and 39% in the treatment arm, and at 62, 49, and 49% in the observation arm (log rank P=0.2398). Stage-adapted subanalyses revealed no survival advantages of treatment over observation, as well. Our results established that there was no relapse-free survival benefit and the overall survival was inferior with an adjuvant 8-week-outpatient sc-rIL-2/sc-rIFN-alpha2a/iv-5-FU-based immunochemotherapy compared to observation in high-risk renal cell carcinoma patients following radical tumour nephrectomy." @default.
• W2034932355 created "2016-06-24" @default.
• W2034932355 creator A5003735608 @default.
• W2034932355 creator A5018573703 @default.
• W2034932355 creator A5025966594 @default.
• W2034932355 creator A5045651628 @default.
• W2034932355 creator A5048112252 @default.
• W2034932355 creator A5049106859 @default.
• W2034932355 creator A5053922377 @default.
• W2034932355 creator A5065852941 @default.
• W2034932355 creator A5067735551 @default.
• W2034932355 creator A5070716784 @default.
• W2034932355 creator A5070774491 @default.
• W2034932355 creator A5072285845 @default.
• W2034932355 date "2005-03-01" @default.
• W2034932355 modified "2023-10-17" @default.
• W2034932355 title "Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)" @default.
• W2034932355 cites W1755178355 @default.
• W2034932355 cites W1769511668 @default.
• W2034932355 cites W1875468008 @default.
• W2034932355 cites W1914396593 @default.
• W2034932355 cites W1966497667 @default.
• W2034932355 cites W1967884480 @default.
• W2034932355 cites W2039686376 @default.
• W2034932355 cites W2047301850 @default.
• W2034932355 cites W2050181929 @default.
• W2034932355 cites W2117838810 @default.
• W2034932355 cites W2133157945 @default.
• W2034932355 cites W22756235 @default.
• W2034932355 cites W2327594577 @default.
• W2034932355 cites W4293241248 @default.
• W2034932355 doi "https://doi.org/10.1038/sj.bjc.6602443" @default.
• W2034932355 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2361915" @default.
• W2034932355 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15756254" @default.
• W2034932355 hasPublicationYear "2005" @default.
• W2034932355 type Work @default.
• W2034932355 sameAs 2034932355 @default.
• W2034932355 citedByCount "167" @default.
• W2034932355 countsByYear W20349323552012 @default.
• W2034932355 countsByYear W20349323552013 @default.
• W2034932355 countsByYear W20349323552014 @default.
• W2034932355 countsByYear W20349323552015 @default.
• W2034932355 countsByYear W20349323552016 @default.
• W2034932355 countsByYear W20349323552017 @default.
• W2034932355 countsByYear W20349323552018 @default.
• W2034932355 countsByYear W20349323552019 @default.
• W2034932355 countsByYear W20349323552020 @default.
• W2034932355 countsByYear W20349323552021 @default.
• W2034932355 countsByYear W20349323552022 @default.
• W2034932355 countsByYear W20349323552023 @default.
• W2034932355 crossrefType "journal-article" @default.
• W2034932355 hasAuthorship W2034932355A5003735608 @default.
• W2034932355 hasAuthorship W2034932355A5018573703 @default.
• W2034932355 hasAuthorship W2034932355A5025966594 @default.
• W2034932355 hasAuthorship W2034932355A5045651628 @default.
• W2034932355 hasAuthorship W2034932355A5048112252 @default.
• W2034932355 hasAuthorship W2034932355A5049106859 @default.
• W2034932355 hasAuthorship W2034932355A5053922377 @default.
• W2034932355 hasAuthorship W2034932355A5065852941 @default.
• W2034932355 hasAuthorship W2034932355A5067735551 @default.
• W2034932355 hasAuthorship W2034932355A5070716784 @default.
• W2034932355 hasAuthorship W2034932355A5070774491 @default.
• W2034932355 hasAuthorship W2034932355A5072285845 @default.
• W2034932355 hasBestOaLocation W20349323551 @default.
• W2034932355 hasConcept C126322002 @default.
• W2034932355 hasConcept C126894567 @default.
• W2034932355 hasConcept C141071460 @default.
• W2034932355 hasConcept C2776694085 @default.
• W2034932355 hasConcept C2776755627 @default.
• W2034932355 hasConcept C2777472916 @default.
• W2034932355 hasConcept C2777546739 @default.
• W2034932355 hasConcept C2780091579 @default.
• W2034932355 hasConcept C2780227381 @default.
• W2034932355 hasConcept C2780790343 @default.
• W2034932355 hasConcept C2781068499 @default.
• W2034932355 hasConcept C2781413609 @default.
• W2034932355 hasConcept C71924100 @default.
• W2034932355 hasConceptScore W2034932355C126322002 @default.
• W2034932355 hasConceptScore W2034932355C126894567 @default.
• W2034932355 hasConceptScore W2034932355C141071460 @default.
• W2034932355 hasConceptScore W2034932355C2776694085 @default.
• W2034932355 hasConceptScore W2034932355C2776755627 @default.
• W2034932355 hasConceptScore W2034932355C2777472916 @default.
• W2034932355 hasConceptScore W2034932355C2777546739 @default.
• W2034932355 hasConceptScore W2034932355C2780091579 @default.
• W2034932355 hasConceptScore W2034932355C2780227381 @default.
• W2034932355 hasConceptScore W2034932355C2780790343 @default.
• W2034932355 hasConceptScore W2034932355C2781068499 @default.
• W2034932355 hasConceptScore W2034932355C2781413609 @default.
• W2034932355 hasConceptScore W2034932355C71924100 @default.
• W2034932355 hasIssue "5" @default.
• W2034932355 hasLocation W20349323551 @default.
• W2034932355 hasLocation W20349323552 @default.
• W2034932355 hasLocation W20349323553 @default.
• W2034932355 hasLocation W20349323554 @default.
• W2034932355 hasOpenAccess W2034932355 @default.
• W2034932355 hasPrimaryLocation W20349323551 @default.
• W2034932355 hasRelatedWork W1828382869 @default.

• next